[Comparative study of low molecular dextran or hydroxyethyl starch as a volume substitute in hemodilution therapy].
Rheological therapy, as an immediate treatment in conjunction with physical therapy and the removal of risk factors, plays a significant role in the management of patients with peripheral vascular disease experiencing reduced walking tolerance. An essential element of rheological therapy is hemodilution. Currently, is still uncertain which plasma substitute solution would be the most appropriate in such cases. This study compared the effectiveness of low molecular hydroxyethyl starch to low molecular dextran during a 16-day hemodilution in combination to physical therapy. The clinical improvement observed with both plasma substitute solutions was comparable, yet in view of the cardiac volume overload, dextran demonstrates greater circulatory stress due to the transient pressure increase and more side effects. For this reason, we prefer to administer low or middle molecular hydroxyethyl starch in the dilution treatment of peripheral arterial occlusive disease as a chronic degenerative vascular disease.
H
H
Kiesewetter
F
F
Jung
J
J
Blume
B
B
Bulling
R P
RP
Franke
D000328:Adult; D000368:Aged; D001794:Blood Pressure / Q000187:drug effects; D001809:Blood Viscosity / Q000187:drug effects; D001810:Blood Volume / Q000187:drug effects; D003131:Combined Modality Therapy; D003911:Dextrans / Q000627:therapeutic use*; D004903:Erythrocyte Aggregation / Q000187:drug effects; D005260:Female; D005340:Fibrinogen / Q000378:metabolism; D006438:Hemodilution / Q000379:methods*; D006801:Humans; D006895:Hydroxyethyl Starch Derivatives / Q000627:therapeutic use*; D007383:Intermittent Claudication / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D008970:Molecular Weight; D011897:Random Allocation; D012212:Rheology; D013213:Starch / Q000031:analogs & derivatives*
D003911:Dextrans; D006895:Hydroxyethyl Starch Derivatives; D005340:Fibrinogen; D013213:Starch
Vergleichende Untersuchung von niedermolekularem Dextranoder Hydroxyäthylstärkelösungen als Volumenersatzmittel bei Hämodilutionstherapie.